Zepbound
Enter your prices
Uses a 28-day refill interval.
Weight Loss
All Treatments
Resources
All Treatments
Weight Loss Treatments
Tirzepatide
Semaglutide
Wegovy Pill
Resources
Healthi App
Blog
Member Meetings
Recipes
Podcast
Patient Sign in
If you're choosing between Zepbound and HealthiCare's Personalized Tirzepatide, the practical question is usually how you plan to pay. If insurance or the LillyDirect self-pay terms make Zepbound work for your budget, that path can fit well. If you're paying cash and want one predictable amount that covers the medication along with the clinical care around it, HealthiCare is built for that.
If you're choosing between Zepbound and HealthiCare's Personalized Tirzepatide, the practical question is usually how you plan to pay. If insurance or the LillyDirect self-pay terms make Zepbound work for your budget, that path can fit well. If you're paying cash and want one predictable amount that covers the medication along with the clinical care around it, HealthiCare is built for that.
Both options use tirzepatide as the active ingredient. Zepbound is Eli Lilly's brand-name medication, approved by the FDA for its labeled uses. HealthiCare's Personalized Tirzepatide is a cash-pay telehealth program where a licensed clinician reviews your intake, decides whether treatment is appropriate, and stays involved through ongoing care that is included in the monthly price.
Because the two are prepared differently, they are not interchangeable, and Zepbound's specific approval and trial results describe Zepbound rather than HealthiCare's preparation. The more useful question is which option actually fits your situation, and that is what the rest of this comparison is here to help you sort out.
Jump to the six-month cost calculator
| Comparison point | Zepbound | HealthiCare Personalized Tirzepatide |
|---|---|---|
| Active ingredient | Tirzepatide (dual GIP/GLP-1 receptor agonist) | Tirzepatide |
| Regulatory status | FDA-approved brand medication with reviewed label and manufacturing | Personalized preparation through HealthiCare's telehealth program, not FDA approved |
| What it treats | Long-term weight reduction and maintenance in specified adults, and moderate-to-severe obstructive sleep apnea in adults with obesity, alongside diet and activity | Weight management through HealthiCare's program, with a licensed clinician determining whether treatment is appropriate |
| Dosing | Starts at 2.5 mg once weekly for four weeks as an initiation dose, not a maintenance dose. Maintenance depends on the indication. Maximum 15 mg weekly | A licensed clinician determines your dose after review |
| How it's given | Subcutaneous injection in the presentations described on the label | Confirm the exact dispensed form, concentration, inactive ingredients, and device details for your prescription |
| Current cash price | LillyDirect self-pay: $299 for 2.5 mg and $399 for 5 mg. Doses of 7.5, 10, 12.5, and 15 mg are $449 through the Journey Program when the refill is purchased within 45 days of the previous delivery or receipt. Outside that 45-day window, regular prices are $499 for 7.5 mg and $699 for 10, 12.5, and 15 mg. 28-day supply | $264 per month, or a $224.40 monthly equivalent billed $673.20 every three months, a 15% saving versus the monthly plan |
| What the price includes | Medication at the prices listed on LillyDirect | Medication ($135), clinical consultation ($30), prescription preparation ($10), shipping and handling ($25), telehealth platform ($20), and HealthiCare service ($44). No separate membership, no contract, cancel anytime, FSA and HSA eligible. Your medication price does not increase when the clinician changes your dose |
| Insurance | May be lower with coverage or savings eligibility | Cash pay, with FSA and HSA eligibility |
Prices in this category change. Confirm current terms on the Zepbound prescribing information, the LillyDirect Zepbound page, the LillyDirect full terms and conditions, and the HealthiCare Personalized Tirzepatide page before you pay.
Use the cash prices you expect to pay. The calculator follows each option's billing interval so a 28-day refill is not treated as the same thing as a calendar-month charge.
Uses a 28-day refill interval.
Uses calendar-month billing.
This calculator adds the charges entered over six calendar months. It is not a quote and does not determine eligibility, treatment, dose, coverage, taxes, refunds, cancellation balances, or future prices. Confirm current terms before paying.
If HealthiCare fits, the next step is an online intake. A licensed clinician reviews it and decides whether treatment is appropriate. Intake alone does not guarantee eligibility, a prescription, or a delivery date.
The best-known trial data for tirzepatide in weight management is SURMOUNT-1. It randomized 2,539 adults with a BMI of at least 30, or at least 27 with a weight-related complication, excluding people with diabetes. Participants received 5 mg, 10 mg, or 15 mg of tirzepatide, or placebo, once weekly for 72 weeks, including a 20-week dose escalation. Mean weight change at week 72 was minus 15.0%, minus 19.5%, and minus 20.9% across the three doses, compared with minus 3.1% for placebo.
Those numbers are group averages for the branded tirzepatide regimen studied in that population. They give you a reasonable sense of what tirzepatide at those doses produced on average. They are not a promise for any individual, and they are not product-specific evidence for HealthiCare's preparation.
The current Zepbound label carries a boxed warning about thyroid C-cell tumors observed in rats, with unknown relevance to humans. Zepbound is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and in anyone who has had a serious hypersensitivity reaction to tirzepatide or to Zepbound excipients. The most common adverse reactions listed include nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection-site reactions, fatigue, hypersensitivity reactions, belching, hair loss, and gastroesophageal reflux.
HealthiCare's program includes review by a licensed clinician to determine whether Personalized Tirzepatide is appropriate for you. Because Zepbound's label applies specifically to Zepbound, its product-specific evidence and warnings should not be assumed to apply identically to other preparations. You can also review the FDA's information about unapproved GLP-1 drugs used for weight loss as part of an informed decision.
There is no direct dose conversion between Zepbound and HealthiCare's Personalized Tirzepatide, and no substitution schedule you should apply on your own. Any change requires a licensed clinician to evaluate the exact products, your current dose, your tolerance, and your health history.
No. They share an active ingredient, but Zepbound is an FDA-approved brand medication with a reviewed label and manufacturing controls, while HealthiCare's Personalized Tirzepatide is prepared through our telehealth program and is not FDA approved. Equivalence between the two has not been established, so they should not be treated as generics of one another.
HealthiCare's personalized Tirzepatide program is cash pay, and you can complete an intake for review by a licensed clinician. There is no automatic substitution from Zepbound, and intake does not guarantee eligibility or a prescription. A licensed clinician decides whether treatment is appropriate for you.
No. A licensed clinician reviews your intake and decides whether treatment is appropriate. Intake does not guarantee eligibility, a prescription, or a delivery date.
HealthiCare's program is cash pay and is FSA and HSA eligible. It is not billed through medical insurance.
Your medication price within the program does not increase when the clinician changes your dose. Billing stays $264 monthly or $673.20 every three months, whichever plan you choose.
Predictable cash pricing includes the medication and clinical care, with no separate membership fee.
Start your weight loss journeyA licensed clinician reviews your intake. Completing it does not guarantee eligibility or a prescription.
This article provides general information and is not medical advice. Talk with a licensed clinician about whether tirzepatide, in any form, is appropriate for your individual health situation.
August 20, 2026
